Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Offering both colonoscopy and at-home tests doubled colorectal cancer screening

Written by | 19 May 2024

The rate of colorectal cancer screenings more than doubled when patients were given a choice between which type of screening they wanted—a take-home kit or colonoscopy—compared to those… read more.

FDA approves Anktiva, (N-803, or nogapendekin alfa inbakicept-pmln) first-in-class IL-15 receptor agonist for BCG-unresponsive non-muscle invasive bladder cancer – ImmunityBio

Written by | 6 May 2024

ImmunityBio, Inc. an immunotherapy company, announced that the FDA has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive… read more.

Frequently need to pee? App-based therapy can help, finds research

Written by | 15 Apr 2024

Combining pelvic floor exercises with behavioral therapy could be more effective than current medical treatments at helping men with frequent urges to urinate, new research in men has… read more.

The Lancet: Prostate cancer cases expected to double worldwide between 2020 and 2040, new analysis suggests

Written by | 14 Apr 2024

Cases of prostate cancer are projected to double from 1.4 million per year in 2020 to 2.9 million per year by 2040, with low- and middle-income countries (LMICs)… read more.

Positive CHMP opinion for Xtandi (enzaltamide) in additional recurrent early prostate cancer treatment setting – Astellas

Written by | 30 Mar 2024

Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Xtandi (enzalutamide)… read more.

Drug-pricing program improved prostate cancer treatment adherence

Written by | 26 Mar 2024

Prostate cancer patients receiving care at hospitals that are part of a special drug-pricing program were more likely to stick to their prescription drug therapy than patients at… read more.

FDA approves Opdivo (nivolumab), plus cisplatin and gemcitabine, for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma – BMS

Written by | 17 Mar 2024

Bristol Myers Squibb announced that the FDA approved Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial… read more.

An overgrowth of nerve cells appears to cause lingering symptoms after recurrent UTIs

Written by | 6 Mar 2024

A perplexing problem for people with recurring urinary tract infections (UTIs) is persistent pain, even after antibiotics have successfully cleared the bacteria. Now Duke Health researchers have identified… read more.

Palliative care is underused for patients with malignant urinary obstruction

Written by | 2 Jan 2024

Less than half of patients with malignant ureteral obstruction (MUO) – a serious complication of advanced cancer, with a poor prognosis – receive palliative care (PC) for their… read more.

Study: Colon cancer screenings are more effective than previously understood

Written by | 23 Dec 2023

Screening for colon cancer reduces cancer rates by substantially more than previous analyses of randomized trials suggest, according to a study co-authored by an MIT economist that takes… read more.

FGFR inhibitor erdafitinib for urothelial cancer is filed in Japan – Janssen Pharmaceutical

Written by | 1 Dec 2023

Janssen Pharmaceutical has filed a new drug application in Japan for its oral fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor erdafitinib for the treatment of certain patients… read more.

FDA approval for DefenCath (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections – CorMedix

Written by | 21 Nov 2023

CorMedix Inc. announced that the FDA has approved DefenCath (taurolidine and heparin) catheter lock solution (CLS) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.